Combinations of a long-acting β₂ agonist; is it BI-1744-CL?

Abstract

These two applications claim novel formulations of long-acting β₂ agonists and a second agent, for example, tiotropium bromide. The first application claims solution formulations of the compounds, the second claims dry powder formulations of essentially the same combinations (the amine salts). The use of several 6-hydroxy-8-([1-hydroxy-1,1-dimethyl-ethylamino-2phenyl]-ethyl)-4H-benzo(1,4)oxazin-3-one β₂ agonists is claimed so it is not possible to unambiguously identify the preferred compound. It is probable that one of these compounds is Beoheringer Ingelheim's clinical candidate BI-1744-CL, which is being developed for the treatment of asthma and chronic obstructive pulmonary disorder.

Keywords::

• aerosol
• asthma
• β adrenoceptor
• β₂ agonist
• BI-1744-CL
• COPD
• drug combination
• tiotropium bromide